ArticleActa histochemica et cytochemica2011
Thalidomide prevents the progression of peritoneal fibrosis in mice.
Article in Acta histochemica et cytochemica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.Inflammopharmacology · 2023Review
- Thalidomide Suppresses Angiogenesis Through the Signal Transducer and Activator of Transcription 3/SP4 Signaling Pathway in the Peritoneal Membrane.Frontiers in physiology · 2021Article
- Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.International journal of molecular sciences · 2019Review
- Renal-protective effect of thalidomide in streptozotocin-induced diabetic rats through anti-inflammatory pathway.Drug design, development and therapy · 2018Article
- Silk fibroin hydrogel as physical barrier for prevention of post hernia adhesion.Hernia : the journal of hernias and abdominal wall surgery · 2017Article
- Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.Journal of the American Society of Nephrology : JASN · 2016Article
- New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models.Acta histochemica et cytochemica · 2014Article
- Function of the transforming growth factor-β1/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis.Experimental and therapeutic medicine · 2014Article
- Intratracheal Administration of Recombinant Human Keratinocyte Growth Factor Promotes Alveolar Epithelial Cell Proliferation during Compensatory Lung Growth in Rat.Acta histochemica et cytochemica · 2013Article
- TGF-β Signaling Regulates Pancreatic β-Cell Proliferation through Control of Cell Cycle Regulator p27 Expression.Acta histochemica et cytochemica · 2013Article
- Involvement of leptin in the progression of experimentally induced peritoneal fibrosis in mice.Acta histochemica et cytochemica · 2013Article
- Tamoxifen decreases the myofibroblast count in the healing bile duct tissue of pigs.Clinics (Sao Paulo, Brazil) · 2013Article
- Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.International journal of clinical and experimental pathology · 2012Article
- SAHA Suppresses Peritoneal Fibrosis in Mice.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
- The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalidomide is clinically recognized as a therapeutic agent for multiple myeloma and has been known to exert anti-angiogenic actions. Recent studies have suggested the involvement of angiogenesis in the progression of peritoneal fibrosis. The present study investigated the effects of thalidomide on the development of peritoneal fibrosis induced by injection of chlorhexidine gluconate (CG) into the mouse peritoneal cavity every other day for 3 weeks. Thalidomide was given orally every day. Peritoneal tissues were dissected out 21 days after CG injection. Expression of CD31 (as a marker of endothelial cells), proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), α-smooth muscle actin (as a marker of myofibroblasts), type III collagen and transforming growth factor (TGF)-β was examined using immunohistochemistry. CG group showed thickening of the submesothelial zone and increased numbers of vessels and myofibroblasts. Large numbers of VEGF-, PCNA-, and TGF-β-positive cells were observed in the submesothelial area. Thalidomide treatment significantly ameliorated submesothelial thickening and angiogenesis, and decreased numbers of PCNA- and VEGF-expressing cells, myofibroblasts, and TGF-β-positive cells. Moreover, thalidomide attenuated peritoneal permeability for creatinine, compared to the CG group. Our results indicate the potential utility of thalidomide for preventing peritoneal fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.